Lexaria Bioscience

Lexaria Bioscience (NASDAQ: LEXX), formerly Lexaria Corp (renamed April 2016), is a Kelowna, British Columbia-based biotechnology company (incorporated 2004) whose sole asset is the patented DehydraTECH drug delivery platform, which enhances the oral bioavailability, absorption, and tolerability of lipophilic active pharmaceutical ingredients — applied to GLP-1 and GIP drugs, pain medications, hormones, and vitamins. Lexaria has investigated DehydraTECH with a variety of APIs in oral formats since 2016, including GLP-1 drug programs. On August 3, 2026 the company effected a 1-for-15 reverse stock split of its common stock to regain Nasdaq compliance and stabilize its share structure, with a CUSIP change to 52886N604.